PHAXIAM Therapeutics S.A. Cash Flow-to-Debt Ratio
PHAXIAM Therapeutics S.A. cash flow-to-debt ratio. PHAXIAM Therapeutics S.A. (PHXM) has a Cash Flow-to-Debt Ratio of -0.35x as of June 2024, meaning its operating cash flow of €-8.34 Million could theoretically repay 0% of its total liabilities (€23.66 Million) in one year. Check PHAXIAM Therapeutics S.A. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of PHAXIAM Therapeutics S.A. (2012–2023)
Cash flow-to-debt ratio of PHAXIAM Therapeutics S.A. from 2012 to 2023. Historical debt coverage capacity for PHAXIAM Therapeutics S.A. across 12 annual periods. Check PHXM capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
PHAXIAM Therapeutics S.A. Cash Flow-to-Debt Ratio by Year (2012–2023)
PHAXIAM Therapeutics S.A. cash flow-to-debt ratio by year from 2012 to 2023. Year-by-year debt coverage analysis for PHAXIAM Therapeutics S.A.. For the full cash flow conversion analysis, see PHXM operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -0.95x | €-24.43 Million | €25.70 Million | ▲ +33.7% |
| 2022 | -1.43x | €-31.99 Million | €22.32 Million | ▼ -10.1% |
| 2021 | -1.30x | €-57.14 Million | €43.92 Million | ▼ -34.6% |
| 2020 | -0.97x | €-52.05 Million | €53.86 Million | ▲ +26.7% |
| 2019 | -1.32x | €-43.51 Million | €32.99 Million | ▲ +25.3% |
| 2018 | -1.77x | €-39.27 Million | €22.24 Million | ▲ +1.0% |
| 2017 | -1.78x | €-24.70 Million | €13.84 Million | ▲ +5.6% |
| 2016 | -1.89x | €-17.64 Million | €9.33 Million | ▲ +23.8% |
| 2015 | -2.48x | €-14.58 Million | €5.87 Million | ▼ -64.0% |
| 2014 | -1.51x | €-7.24 Million | €4.78 Million | ▼ -2.0% |
| 2013 | -1.48x | €-6.47 Million | €4.36 Million | ▼ -3484.0% |
| 2012 | 0.04x | €621.40K | €14.17 Million | — |